Trial reportDigestive diseases and sciences2002
Effect of esomeprazole 40 mg vs omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease.
Trial report in Digestive diseases and sciences, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 92 citations in OpenAlex.
- Pilot, Randomized, Blinded, Placebo-Controlled Trial Investigating the Correlation Between Acid Control and Heartburn Relief with 14 Days of Esomeprazole Treatment.Advances in therapy · 2018Trial
- Pharmacokinetics and Acid Suppressant Efficacy of Esomeprazole after Intravenous, Oral, and Subcutaneous Administration to Healthy Beagle Dogs.Journal of veterinary internal medicine · 2017Trial
- Comparative study of omeprazole, lansoprazole, pantoprazole and esomeprazole for symptom relief in patients with reflux esophagitis.World journal of gastroenterology · 2009Trial
- A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis.Digestive diseases and sciences · 2006Trial
- Inhibition of pentagastrin-stimulated gastric acid secretion by pantoprazole and omeprazole in healthy adults.Digestive diseases and sciences · 2006Trial
- Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg in patients with gastro-oesophageal reflux symptoms.European journal of clinical pharmacology · 2004Trial
- Esomeprazole Decreases Soluble Fms-like Tyrosine Kinase-1 in Preeclamptic Pregnancy in Rats.International journal of molecular sciences · 2026Article
- Phytochemical constituents ofJournal of enzyme inhibition and medicinal chemistry · 2025Article
- Prediction for optimal dosage of pazopanib under various clinical situations using physiologically based pharmacokinetic modeling.Frontiers in pharmacology · 2022Article
- Bioequivalence of two esomeprazole magnesium enteric-coated formulations in healthy Chinese subjects.World journal of clinical cases · 2020Article
- A randomized, crossover pharmacodynamic study of immediate-release omeprazole/sodium bicarbonate and delayed-release lansoprazole in healthy adult volunteers.Pharmacology research & perspectives · 2016Article
- Comparative efficacy of esomeprazole and omeprazole: Racemate to single enantiomer switch.Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences · 2015Article
- Clinical utility of esomeprazole for treatment of gastroesophageal reflux disease in pediatric and adolescent patients.Adolescent health, medicine and therapeutics · 2012Review
- Clinical implications of the nelfinavir-proton pump inhibitor drug interaction in patients with human immunodeficiency virus.Pharmacotherapy · 2011Article
- Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.European journal of clinical pharmacology · 2009Article
- Esomeprazole: a review of its use in the management of gastric acid-related diseases in adults.Drugs · 2008Review
- A review of esomeprazole in the treatment of gastroesophageal reflux disease (GERD).Therapeutics and clinical risk management · 2007Article
- Clinical response (remission of symptoms) in erosive and non-erosive gastro-oesophageal reflux disease.Drugs · 2005Review
- Review
- Gastric function measurements in drug development.British journal of clinical pharmacology · 2003Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Maintenance of intragastric pH > 4 is vital for effective management of gastroesophageal reflux disease (GERD). Esomeprazole 40 mg, the first proton pump inhibitor developed as an optical isomer, demonstrates improved acid inhibition over omeprazole 20 mg. Our aim was to compare esomeprazole 40 mg with omeprazole 40 mg, once-daily, on intragastric acidity in patients with symptoms of GERD. In this open-label, crossover study, 130 patients with symptoms of GERD received esomeprazole 40 mg or omeprazole 40 mg once-daily for five days. The 24-hr intragastric pH was monitored on days 1 and 5 of each treatment period. The mean percentage of the 24-hr period with intragastric pH > 4 was significantly greater (P < 0.001) with esomeprazole 40 mg than with omeprazole 40 mg on days 1 (48.6% vs 40.6%) and 5 (68.4% vs 62.0%). Interpatient variability was significantly less with esomeprazole than omeprazole. Esomeprazole was well tolerated. In conclusion, esomeprazole 40 mg provides more effective acid control than twice the standard dose of omeprazole.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.